Accelerating Preclinical Alzheimer’s Clinical Trials through a Trial-Ready Cohort with Diverse Representation - 21/11/24
Doi : 10.14283/jpad.2020.43
A.K.W. Lee 1, 2, S. Correia 1, 2, Stephen P. Salloway 1, 2, 3, ⁎ 
1 Memory and Aging Program, Butler Hospital, Providence, RI, USA
2 Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
3 Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA
c SSalloway@Butler.org
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Il testo completo di questo articolo è disponibile in PDF.
| Conflict of interest: Dr. Lee is one of the institutional site Pis of the TRC-PAD study (Butler Hospital site). Dr. Salloway reports grants, personal fees and non-financial support from Biogen and Lilly, grants and personal fees from Eisai and Avid, personal fees and non-financial support from Novartis and Roche, and personal fees from Genentech, outside the submitted work. Dr. Correia has nothing to disclose. |
© 2020
THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 7 - N° 4
P. 204-205 - Settembre 2020 Ritorno al numero
Articolo precedente
- Establishing a Trial Ready Cohort to Accelerate Alzheimer’s Clinical Trial Enrollment and Treatments
- E.A. Meyers, Maria C. Carrillo
- The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) — A Fundamental Ally in AD Prevention Research
- A.P. Porsteinsson, E.D. Clark
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.